We have analyzed by different immunological methods the proteolytic degradation of cardiac troponin I (cTnI) in human necrotic tissue and in serum. cTnI is susceptible to proteolysis, and its degradation leads to the appearance of a wide diversity of proteolytic peptides with different stabilities. N-and C-terminal regions were rapidly cleaved by proteases, whereas the fragment located between residues 30 and 110 demonstrated substantially higher stability, possibly because of its protection by TnC. We conclude that antibodies selected for cTnI sandwich immunoassays should preferentially recognize epitopes located in the region resistant to proteolysis. Such an approach can be helpful for a much needed standardization of cTnI immunoassays and can improve the sensitivity and reproducibility of cTnI assays.
The cardiac-specific isoform of troponin I (cTnI) 7 has been known as a marker of heart damage for Ͼ10 years (1, 2) . At present cTnI is considered to be one of the most specific and sensitive markers of myocardial cell death (3) (4) (5) (6) . However, clinical chemists and physicians diagnosing and treating acute myocardial infarction (AMI) patients are puzzled by the up to 10-fold differences in cutoff values and even larger differences in measured concentration (7, 8) obtained by different assays.
Differences in the measured cTnI concentration using various assays can be explained by the lack of a common calibration standard and/or by the differing cross-reactivities of antibodies with the different cTnI forms (7) . Recently it was demonstrated that the major fraction of cTnI in the circulation of AMI patients is complexed with troponin C (TnC) (7, 9) . Monoclonal antibodies (MAbs) differ in their ability to recognize free cTnI and cTnI complexed with TnC, and this fact can be the source of disagreement between assays (7, 9) .
Necrosis of cardiac tissue caused by infarction is accompanied by liberation of proteolytic enzymes from lysosomes. Because cTnI is highly susceptible to proteolysis (10) , necrosis can be expected to induce substantial degradation of cTnI. This means that, depending on conditions (e.g., time after onset of AMI, size of infarction zone, and rate of reperfusion), the blood of AMI patients will contain variable quantities of intact cTnI and its proteolytic fragments, which can circulate in free form or in complexes with the two other troponin components.
In the present study, we followed the process of proteolytic degradation of cTnI in necrotic tissue and in serum by two immunological methods: sandwich immunoassay and Western blots utilizing MAbs with different epitope specificity. We demonstrated that during incubation in necrotic cardiac tissue as well as in serum cTnI undergoes rapid proteolytic cleavage and that different fragments of the cTnI molecule have different stabilities. The region most resistant to proteolysis is the region located between amino acid residues 30 and 110.
Materials and Methods reagents
Reagents for gel electrophoresis and Western blots, goat anti-mouse IgG polyclonal antibodies conjugated with peroxidase, urea, EDTA, phenylmethylsulfonyl fluoride, pepstatin A, and benzamidine chloride were obtained from Sigma Chemical Co. The nitrocellulose membrane was from Bio-Rad. The stable fluorescent chelate of Eu 3ϩ [chelate of 2,2Ј,2ЈЈ,2ЈЈЈ-{{4-[4-(iodoacetamido)phenyl-ethynyl]pyridine-2,6-diyl}bis(methylenenitrolo)} tetrakis(acetic acid)], the isothiocyanate derivative of biotin, streptavidin-coated plates, and LANFIA solution were from Wallac Oy. The Immobilon membrane was from Millipore, and the CNBr-activated Sepharose 4B was from Pharmacia Biotech. Normal human serum was from Scantibodies Laboratory, Inc. The human cardiac troponin complex (intact ternary complex), human cTnI, and MAbs specific to cTnI were from HyTest. All MAbs (except MAb 6F9) are highly specific to cTnI and have no detectable cross-reactivity with skeletal TnI or human TnC or cardiac troponin T (9, 11) . MAb 6F9 recognizes both cardiac and skeletal forms of the protein. The epitope mapping of the MAbs used in the present study, with the exception of MAb 6F9, is described elsewhere (11) . The details of cTnI epitope mapping were described earlier (11, 12) .
one-step sandwich immunofluorometric assay
The protocol of the assay was similar to that described by Katrukha et al. (9) with minor modifications. Briefly, capture MAbs were biotinylated, and detection MAbs were labeled with the stable chelate of Eu 3ϩ . The mixture of antigen (AMI serum samples or reconstituted in normal human serum) with capture and detection MAbs was incubated for 30 min at room temperature in streptavidincoated plates. After the plates were washed, LANFIA enhancement solution (0.2 mL/well) was added, and incubation was continued for 3 min at room temperature with gentle shaking. The fluorescence (cps) was measured with the 1234 DELFIA Plate Fluorometer. The fluorescence of the control probe, which did not contain coating MAbs and which reflected the nonspecific binding of cTnI, was subtracted from the total fluorescence. The method described has a detection limit below 0.1 g/L, and the linearity range is 0.3-100 g/L. This method provides reliable detection of both free cTnI and cTnI in the whole ternary complex. In the latter case, the incubation mixture contained 5 mmol/L EDTA to reduce interaction between troponin components (9).
serum samples
Serial blood samples from AMI patients were collected at the University Hospital of Turku (Turku, Finland) and at the 29th Moscow City Hospital (Moscow, Russia). Blood samples were incubated 5 min at room temperature and centrifuged, and the serum samples were stored at Ϫ70°C until use. In all cases, the diagnosis of AMI was confirmed by electrocardiogram and serial measurements of creatine kinase, its MB isoenzyme, and lactate dehydrogenase isoenzyme 1. All samples were collected in accordance with the Helsinki Declaration of 1975 as revised in 1983.
in vitro necrosis of human cardiac tissue
To simulate the process of necrosis induced by AMI in vitro, we incubated small pieces (2-3 g) of human cardiac left ventricular tissue, obtained from four different donors 5-8 h postmortem, at 37°C. Tissue samples were wetted with 0.15 mol/L sodium chloride containing 2 g/L sodium azide as a preservative (1 mL of sodium chloride solution per 3 g of tissue) and incubated with gentle shaking for 2, 5, 8, and 20 h. After incubation the tissue samples were frozen and stored at Ϫ70°C.
For protein extraction, each sample was frozen with liquid nitrogen and crushed to powder. Soluble proteins were extracted with 25 mmol/L Tris-HCl buffer (pH 7.5) containing protease inhibitors (0.1 mmol/L phenylmethylsulfonyl fluoride, 1 mol/L pepstatin A, and 10 mmol/L benzamidine chloride) at a ratio of 9 mL of buffer per gram of tissue powder. After incubation for 5 min on ice with gentle shaking, the sample was centrifuged for 2 min at 5000g, and the supernatant was collected. The pellet was washed with the Tris-HCl buffer, and after centrifugation the supernatant was removed carefully. Supernatants were combined, and 6 mol/L solid urea was added.
The pellet after the second centrifugation was subjected to three cycles of extraction by nine volumes of 50 mmol/L Tris-HCl (pH 7.5) containing 6 mol/L urea, 5 mmol/L EDTA, 10 mmol/L 2-mercaptoethanol, and protease inhibitors (0.1 mmol/L phenylmethylsulfonyl fluoride, 1 mol/L pepstatin A, and 10 mmol/L benzamidine chloride). After centrifugation for 2 min at 5000g, the supernatants were collected. All supernatants (containing soluble and contractile proteins) were combined and stored at Ϫ70°C until use. Less than 2% of the initial cTnI remained in the pellet after extraction (determined by Western blot, data not shown).
Immediately after the samples were thawed, the concentration of cTnI in each sample was measured in sandwich immunoassays after addition of 1 volume of extract to 3000 volumes of normal human serum. The concentration of urea after such dilution was low and did not affect the assay results (9) . Protease inhibitors at this dilution also did not affect the assay (data not shown).
n-terminal sequencing of cTnI proteolytic peptide 2
Left ventricular tissue was incubated at 37°C for 8 h, and proteins were extracted as described earlier in this section. The extract was diluted by nine volumes of 20 mmol/L Tris-HCl (pH 8.0) buffer containing 0.6 mol/L LiCl, 5 mmol/L EDTA, and 15 mmol/L 2-mercaptoethanol. The protein solution was centrifuged for 5 min at 5000g, and the supernatant was collected and loaded on an affinity column containing anti-cTnI MAb C5 immobilized on Sepharose [for more details see Katrukha et al. (13) ]. Proteins bound to the affinity matrix were eluted by 0.1 mol/L glycine buffer (pH 2.0) and dialyzed extensively against 10 mmol/L HCl. After lyophilization, the protein mixture was subjected to electrophoresis on a 10 -20% gradient sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred onto a Immobilon PVDF TM membrane. Sequencing of N-terminal amino acid residues of peptide 2 was conducted on a Knauer Protein Sequencer (Knauer), as recommended by the manufacturer.
western blot analysis
Protein samples were separated by electrophoresis on a 10 -20% gradient SDS gel (13) and transferred onto the nitrocellulose membrane as described previously (14) . To block nonspecific binding of the proteins, the nitrocellulose membrane was incubated for 15 min at room temperature in phosphate-buffered saline containing 1 g/L Tween 20 and 5 g/L casein. The membrane was then incubated for 1 h in the same buffer containing 0.02 g/L anti-cTnI MAb and 1 g/L casein. After the nitrocellulose membrane was washed with phosphate-buffered saline containing 1 g/L Tween 20, it was incubated for 2 h with horseradish peroxidase-labeled anti-mouse antibodies, and the binding of MAbs was visualized by incubation with diaminobenzidine.
interaction of cTnI and its proteolytic fragments with TnC Left ventricular tissue was incubated at 37°C for 8 h, and proteins were extracted as described earlier in this section, with omission of EDTA from the extraction buffer. The extract was loaded on a column containing TnC immobilized on Sepharose (5 g of TnC per liter of Sepharose). The column was equilibrated with buffer A (50 mmol/L Tris-HCl, pH 8.0, 7 mol/L urea, 2 mmol/L CaCl 2 , 15 mmol/L 2-mercaptoethanol). Unbound proteins were removed by washing with the same buffer, and the proteins bound to TnC were eluted with buffer B (50 mmol/L Tris-HCl, pH 8.0, 7 mol/L urea, 10 mmol/L EGTA, 15 mmol/L 2-mercaptoethanol). In the control experiment the same volume of urea extract was loaded on a Sepharose column without immobilized TnC. This column was evaluated in the same manner. The proteins bound to the affinity and control matrices were subjected to 10 -20% gradient SDS-polyacrylamide gel electrophoresis, transferred onto the nitrocellulose membrane, and detected by MAbs.
stability of cTnI in serum
Intact human cardiac troponin complex (final concentration of cTnI, 30 g/L) was dissolved in the pooled normal human serum containing 1 g/L sodium azide to prevent bacterial growth. Serum samples from AMI patients were diluted fourfold with the same pooled serum containing 1 g/L sodium azide. Antigen solutions were aliquoted and incubated at 23°C for different periods of time (up to 5 days). After incubation, samples were frozen and stored at Ϫ70°C until use.
Results
The cTnI concentration in the extracts of human cardiac tissue incubated at 37°C for different time periods was determined by five different sandwich fluoroimmunoassays. In four assays, we used the Eu-labeled MAb 16A11 for detection. This MAb recognizes the epitope restricted by residues 87-91, located in the central region of the cTnI molecule (15) . For capture (biotinylated) MAbs, we chose antibodies with epitopes located at different distances from the epitope of the detection MAb (Fig. 1A) .
cTnI demonstrated different degrees of stability when measured in different assays. When epitopes of the cap- ture MAbs were located in the central region of cTnI (19C7-biot-16A11-Eu and 18H7-biot-16A11-Eu), the rate of decline in cTnI immunoreactivity detected by the assays was rather slow. Even after a 20-h incubation period, the measured fluorescence was ϳ50% of the initial value. cTnI immunoreactivity was significantly less stable when the epitope of the capture MAb was located at the extreme N-terminal (14G5) or C-terminal (7F4) ends of cTnI. When the capture and detection MAbs were located on different ends of the molecule (14G5-biot-7F4-Eu), incubation at 37°C dramatically decreased the measured fluorescence. After 20 h of incubation, hardly any antigen was detected by this assay (Fig. 1B) .
We hypothesized that during the incubation of necrotic tissue deep proteolytic degradation of cTnI occurs and that different regions of the cTnI molecule might have different stabilities. To understand which region of the molecule is the most stable, we followed the process of cTnI degradation more closely. Proteins from the tissue extract incubated at 37°C for 8 h were subjected to SDS-gel electrophoresis and subsequent Western blotting. cTnI and its proteolytic fragments were visualized by MAbs with different epitope specificities (Fig. 2) . We were able to differentiate seven main peptides with molecular masses ranging from 14 kDa up to 27-28 kDa. MAbs with epitopes located in the N-and C-terminal regions of the molecule recognized only limited numbers of peptides (Fig. 2, lanes 1, 2 and 8 -10 ), suggesting that the N-and C-terminal peptides of cTnI are easily removed during proteolysis. On the contrary, MAbs 10F4, 19C7, 414, 16A11, and 18H7, which recognize residues 34 -37, 41-49, 56 -61, 87-91, and 102-108 of cTnI, respectively, stain the largest number of peptides, and the peptide pattern stained by these MAbs is very similar (Fig. 2, lanes 3-7) .
Continuing our investigation of cTnI degradation, we analyzed the time course of proteolysis in necrotic tissue. Tissue samples were incubated for 0, 2, 5, 10, and 20 h at 37°C, and the proteins were extracted as described in Materials and Methods. The urea extracts were subjected to SDS-gel electrophoresis and Western blotting. cTnI peptides were visualized by MAb 19C7. This MAb was used because it recognizes the largest number of cTnI peptides (Fig. 2, lane 4) . A tissue sample was obtained from a donor 8 h postmortem. Therefore, without any additional incubation at 37°C, this sample already contained several proteolytic fragments of cTnI (Fig. 3, lane 1) . Incubation of this sample for 2 and 5 h caused accumulation of peptides 2 and 3, with a substantial decrease in the intensity of the intact cTnI band (Fig. 3, lanes 2 and 3) . Prolonged incubation for 8 and 20 h was accompanied by accumulation of short cTnI peptides (peptides 5, 6, and 7) with molecular masses of 17, 16, and 14 kDa, respectively, and by further decreases in the intensities of the intact cTnI band and its two large peptides (peptides 2 and 3).
Because peptide 2 is the main cTnI peptide detected in tissue homogenate after incubation in necrotic tissue (Fig.  3) , we tried to identify the site of protease cleavage. As evident from Fig. 2 , peptide 2, with an apparent molecular mass of 25 kDa, was stained by all MAbs except 10B11 and 4G6; 10B11 and 4G6 recognize epitopes located in the extreme N-terminal end of cTnI. Taking into account the size of peptide 2, one may assume that peptide 2 lacks 24 -28 amino acid residues from the N-terminal region of the cTnI molecule. To verify this suggestion we transferred peptide 2 to Immobilon PVDF and sequenced it on the Knauer protein sequencer. The peptide 2 fraction was not homogeneous; we were able to determine two Nterminal sequences-AYAT and YATE-corresponding to the primary structure of cTnI starting from residues 27 and 28, respectively.
The rate of cTnI proteolysis may depend on different factors, such as the size of the infarction zone, the rate of reperfusion, and some individual biochemical features of the donors. We compared the rate of cTnI proteolysis in tissue samples obtained from two different donors (Fig.  4) . Tissue samples were incubated as described in Materials and Methods for 2-20 h, and the quantity of intact cTnI was determined by the assay utilizing biotinylated MAb 14G5 as the capture antibody and 7F4 as the detecting MAb. Because the epitopes of MAbs utilized in this assay are located at the extreme N-and C-terminal ends of the cTnI molecule, the assay can be used only for the detection of the intact cTnI, not its proteolytic fragments. The rate of cTnI degradation in the two samples tested was different. Twenty hours after the beginning of incubation, we detected only 1.7% of the initial cTnI in the tissue sample from the first donor, whereas after the same time of incubation we detected ϳ15% of the initial cTnI in the sample obtained from the second donor (Fig. 4) .
If our in vitro model correctly reflects the real process of cTnI proteolytic degradation in vivo, we may expect that the apparent kinetics of cTnI released into the bloodstream and the sensitivity of its detection in serum will depend strongly on the specificity of the MAbs used for the sandwich immunodetection. To test this assumption, we measured the concentration of cTnI in serial samples obtained from AMI patients by two different immunoassays. The first assay (assay A) utilizes 19C7 as the coating MAb and 8E10 as the Eu-labeled detection MAb. These MAbs recognize epitopes located close to each other in the central region of cTnI, which is relatively resistant to proteolysis (Fig. 2) . Therefore assay A is suitable for the detection of both intact cTnI and its proteolytic fragments. The second assay (assay B) utilizes 14G5 as the coating biotinylated MAb and 7F4 as the Eu-labeled detecting MAb. The epitopes of these two MAbs are located at opposite ends of the cTnI molecule. Because both the Nand C-terminal ends of cTnI are highly susceptible to proteolytic degradation, the second assay detects intact cTnI but does not detect short cTnI peptides. We used both assays to monitor the cTnI concentration in the serum of AMI patients (Fig. 5) . During the first few hours after the onset of chest pain, both assays give similar results. Twenty hours after the onset of the chest pain, however, the cTnI concentration measured by the first assay was much higher than that measured by the second assay. The ratio of the concentrations was close to 1-1.5 during the first 10 -15 h; 3 days later, however, this ratio increased to 4. In some serum samples collected 5 days after the onset of chest pain, we were unable to detect any increase of cTnI using assay B, whereas at the same time we detected substantial quantities of cTnI, using assay A (data not shown).
To study the process of cTnI degradation in calibrators or AMI serum samples after they were collected, we incubated the troponin complex in normal human serum and serum from AMI patients (see Materials and Methods) for different time periods at room temperature (23°C). The changes in cTnI concentration were determined by three differently configured sandwich fluoroimmunoassays. The assays were constructed using MAb 8E10, which recognizes the epitope located in the central region of the molecule, as the capture MAb. The MAbs used for detection recognize the N-terminal (7F4), C-terminal (14G5), or the central (19C7) regions of the cTnI sequence (Fig. 1A) . Incubation of the ternary complex in the pooled serum as well as cTnI from AMI serum samples for 20 -120 h caused dramatic decreases in the cTnI concentration measured by assays based on 8E10 -7F4 or 8E10 -14G5 (Fig. 6) . At the same time, only a small decrease in cTnI immunoreactivity was observed even after 120 h of incubation when measured by the assay using 19C7-8E10 (Fig. 6) .
We believe that the increased stability of the central region of cTnI can be explained in part by its interaction with TnC, which protects this region of the cTnI molecule from proteolysis. If this is correct, we may expect that the fragments of the cTnI molecule resistant to endogenous proteolysis will retain their ability to interact with TnC. To test this hypothesis, the proteins extracted from the tissue sample incubated at 37°C for 8 h were treated as described in Materials and Methods. cTnI fragments bound to TnC-Sepharose were subjected to SDS-gel electrophoresis and Western blotting. cTnI and its peptides were visual- Tissue samples from two donors were incubated at 37°C as described in Materials and Methods, and the cTnI immunological activity was measured by the 14G5-biot-7F4-Eu assay. The cTnI concentration was measured by sandwich assays using 19C7-biot-8E10-Eu (F) and 14G5-biot-7F4 Eu (f).
ized by staining with MAb 19C7 (Fig. 7) . As seen in Fig. 7 , intact cTnI and most of the endogenous proteolytic fragments were bound to immobilized TnC (Fig. 7) . This interaction is Ca 2ϩ -dependent and is highly specific because cTnI peptides were not retarded on the Sepharose column without immobilized TnC (Fig. 7, lane 3) . Although the relative intensities of the peptide bands in lanes 1 and 2 of Fig. 7 are slightly different, we believe that most of the cTnI peptides were retarded on TnC.
Discussion cTnI is very susceptible to proteolysis. Free cTnI rapidly loses immunological activity after being reconstituted in normal serum and other buffered solutions with physiological pH and concentrations of salts (16) . After clot formation in the coronary vessel, the underlying muscle tissue suffers from severe ischemia, which is followed by necrotization of the ischemic muscle. Necrotization is accompanied by liberation of proteases from lysosomes and proteolytic degradation of different intracellular proteins. cTnI, which is known to be very susceptible to proteolysis, is likely to be one of the first targets of protease attack.
In the present study, we have shown that cTnI in necrotic cardiac tissue is cleaved rapidly by proteases and that this process leads to the disappearance of the intact molecule and accumulation of short fragments of cTnI. Depending on tissue samples, Ͻ10% of cTnI remained in the intact form after 20 h of incubation at 37°C (Figs. 1B  and 3 ). We found that the N-and C-terminal regions of cTnI were extremely unstable and were easily removed when the necrotic tissue was incubated for short periods of times at 37°C. We predicted that if the epitopes of the MAbs used in sandwich immunoassays are well separated from each other, then the probability that the polypeptide chain between these epitopes will be cleaved is rather high. In complete agreement with this prediction, we found that when the epitopes for MAbs were located at the extreme N-terminal (14G5) and C-terminal (7F4) ends of cTnI, very small quantities of cTnI were detected by sandwich immunoassay even after a short (8 h) incubation of tissue at 37°C (Fig. 1B) . Our observation is in agreement with recent data indicating that the N-terminal part of cTnI is very flexible (17) and is more easily exposed to the action of proteases.
The central region of cTnI, located between residues 30 and 110, is more stable and is not cleaved even after extended incubation times (Fig. 2) . It is well known that in the troponin complex, cTnI tightly interacts with TnC. This interaction is Ca 2ϩ -dependent (18, 19) . The central region of cTnI containing the inhibitory peptide interacts with the central helix and C-terminal domain of TnC (19, 20) . Because most of the cTnI proteolytic fragments retain the ability to interact with TnC (Fig. 7) , we believe that the higher resistance to proteolysis of the central region of cTnI can at least partly be explained by its interaction with TnC, which seems to protect it from proteolytic degradation.
The data obtained from our model of necrosis indicate that 20 -40 h after AMI onset, the predominant fraction of cTnI in the bloodstream is not intact cTnI but a heterogeneous mixture of proteolytic fragments and their complexes with TnC. Therefore, the sandwich immunoassays for cTnI should meet several important requirements. The antibodies used in these assays should recognize not only intact free cTnI and its complexes with other troponin components (7, 9) , but also the proteolytic fragments of cTnI and their complexes.
cTnI can undergo proteolytic degradation not only in the necrotic cardiomyocytes but also in the bloodstream of patients or in collected blood/serum samples. The rate of proteolytic degradation in serum depends on many different factors. For example, the stability of free cTnI is much lower than the stability of cTnI inside intact ternary or binary complexes with TnC (16). Here we demonstrated that the detected stability of cTnI in serum also depends on the assay used for the cTnI measurement. This observation can be of interest to manufacturers who produce cTnI assays and prepare cTnI controls or standards from intact troponin complex, using pooled human serum as a matrix, and for clinicians, providing them with information on the length and conditions of serum storage.
For a long time the N-terminal region of cTnI (the first 32 residues) was considered to be the best site for antibody production because this sequence of amino acids is absent in the skeletal isoform of troponin I (15, 21) . Indeed, this region of the molecule is highly immunogenic and absolutely specific for the cardiac isoform of troponin I (11, 12) . However, our results indicate that this region of the molecule as well as the extreme C-terminal end are rapidly cleaved during endogenous proteolysis of cTnI (Figs. 1-3) . Therefore, sandwich immunoassays utilizing one antibody specific to the extreme N-terminal end of cTnI and another antibody recognizing residues in the central or C-terminal regions of cTnI will have lower sensitivity, especially in cases of late AMI diagnosis, compared with assays based on antibodies recognizing the stable region of the protein.
In addition to superior specificity, cTnI has one important advantage over the majority of other markers widely used in clinical practice. cTnI can be detected in the bloodstream of patients 5-7 days after the onset of the first symptoms of AMI, thus enabling late diagnosis, which is impossible with some other markers. This advantage turns into a drawback when reinfarction occurs several days after the first episode. In that case, the concentration of cTnI can be still increased because of the initial AMI, and only serial measurements of cTnI can confirm or reject the new diagnosis. We propose that utilization of two different cTnI assays specific to both intact cTnI and its proteolytic fragments (assay A, 19C7-8E10) and to only intact cTnI (assay B, 7F4 -14G5) will help to discriminate the first AMI from the second infarction. If 10 -15 h after the onset of symptoms (for the second time, several days after first AMI), the ratio of the concentrations measured by assays A and B is high, then one can conclude that it is the first infarction that leads to the gradual liberation of proteolytic fragments of cTnI (Fig.  5B) . If the ratio of fluorescence measured by assays A and B at 10 -15 h after the appearance of the first symptoms is low (close to 1), then one can conclude that additional intact cTnI has been liberated into the bloodstream, which may be explained by a recurrent AMI. The same idea can be used more conveniently in a double-label assay, with a capture MAb recognizing the epitope localized in the stable region of the molecule and two detection MAbs, one recognizing stable regions and the other recognizing unstable regions of the molecule labeled by different labels (Eu 3ϩ and Tb 3ϩ or Fluorescein and Texas Red) that can be clearly detected independently of each other. Currently, such markers as myoglobin and the creatine kinase MB isoenzyme are used for the diagnosis of recurrent AMI; however, the much higher specificity of cTnI can be more valuable in this case.
We conclude that because of high susceptibility to proteolysis, cTnI undergoes rapid degradation after necrosis induced by AMI. A complex mixture of intact cTnI, its proteolytic fragments, and their complexes with other troponin components is liberated into the bloodstream after AMI. The differences in cutoff values and measured cTnI concentrations among the cTnI assays described in the literature can be partially explained by the use in some assays of antibodies that react with unstable epitopes that are rapidly deleted or damaged during proteolysis of cTnI in necrotic cardiac cells or in serum. Therefore, for sensitive and reproducible detection of cTnI in serum, we suggest using antibodies specific to the stable region of the cTnI molecule.
